Nestle Nutritio Patent-Cliff Exposure & CMS Drug Spending Portfolio

Nestle Nutritio (US): 3 reconciled FDA prescription therapies, $758.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$758.7M
2024 Medicare Part D Spend$600.1M
2024 Medicaid Spend$158.6M
California HCAI SB 17 Filings2 WAC filings (max 31.3% 2-yr change)